華潤醫藥(03320.HK)附屬與美國ABS公司達成新冠中和抗體獨家合作
華潤醫藥(03320.HK)宣佈,旗下華潤生物醫藥與美國Ab Studio Inc.已達成戰略合作協議,ABS將ABS-VIR-001項目在全球範圍內的開發和商業化權利授權給華潤生物,華潤生物支付一定的裏程碑費用及銷售分成。
公司表示,ABS-VIR-001抗體是一款利用計算機模擬建模及3D分析技術,針對新冠病毒S1蛋白三個抗原表位而設計的三特異性抗體,可用於新冠肺炎的治療和預防,該抗體在結構設計、生產成本、藥效學、分子量、給藥方式(鼻腔給藥用於預防)、依從性等方面具有一定優勢,預期引進該產品有助於華潤醫藥深入佈局新冠肺炎領域,進一步提升華潤醫藥綜合競爭實力且爲股東帶來持續回報。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.